Fig. 3

Pluripotency of MenSCs incubated with PRP. a Flow cytometry analysis of MSC surface markers CD34, CD38, CD44, CD45, CD73, CD90, CD105, and SSEA4 (n = 6). Red lines for PRP, blue lines for FBS. CD105 was significantly increased after PRP treatment for 24 h, P < 0.05. b Immunofluorescence assays of SUSD2, CD146, Vimentin, and CK18 (red or green), DAPI was used to stain nuclei (blue) (n = 6). c Perivascular markers SUSD2 and CD146 co-expression assessed by flow cytometry (P < 0.05, n = 4). d Osteogenic and adipogenic differentiation of MenSCs treated with 10% PRP or 10% FBS for 21 days (×100), staining by Alizarin Red for calcium nodules and Oil Red for lipid droplets after fixation (n = 3). e Fluorescence intensity analysis of SUSD2, CD146, and Vimentin in B. Data was mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001 for two-tailed t test